CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND TNFα ANTAGONIST DOMAIN Russian patent published in 2019 - IPC C07K16/22 C07K14/48 A61K39/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology and is a binding molecule that contains the NGF antagonist domain (nerve growth factor) and the TNFα antagonist domain (α-tumor necrosis factor), where the NGF antagonist is an antibody to NGF or its antigen-binding fragment, and where the TNFα antagonist domain contains a soluble TNFα-binding fragment of TNFR; where the antibody to NGF or its fragment contains the variable domain of the heavy chain (VH domain), containing a set of hypervariable sites (CDR) HCDR1, HCDR2, HCDR3, and a light chain variable domain (VL domain) containing a set of CDRs LCDR1, LCDR2 and LCDR3, moreover, HCDR1 has an amino acid sequence SEQ ID NO: 4, HCDR2 has an amino acid sequence SEQ ID NO: 5, HCDR3 has the amino acid sequence of any of SEQ ID NO: 6, 11 or 12, LCDR1 has an amino acid sequence SEQ ID NO: 8, LCDR2 has an amino acid sequence SEQ ID NO: 9, and LCDR3 has an amino acid sequence SEQ ID NO: 10; where is the TNFα antagonist domain contains an amino acid sequence that is at least 80 % identical to the sequence of SEQ ID NO: 13, or its functional fragment; and where this binding molecule is capable of binding NGF and TNFα. Also the invention relates to an analgesic composition comprising a binding molecule and a carrier.

EFFECT: administration of NGF antagonist and TNFα antagonist, proposed in this invention can control pain in a subject more effectively than administering an equivalent amount of NGF antagonist or TNFα antagonist in the form of monotherapy.

32 cl, 17 dwg, 1 tbl, 8 ex